DOPS OD tablets 100 mg for improving nerve function (droxidopa, Northera)

General information on Japanese DOPS OD tablets 100 mg for improving nerve function (droxidopa, Northera)

Package details: 100 tablets

Manufacturer: Sumitomo Dainippon Pharma Co.,Ltd., Japan

Active ingredient: droxidopa (chemical formula C9H11NO5)

Medical effect: DOPS OD tablets are effective for the treatment of the following diseases and conditions:

1. improve nerve function,
2. improve freezing of gait and dizziness on standing up caused by Parkinson disease,
3. improve orthostatic hypotension, faint and dizziness on standing up caused by Shy-Drager syndrome or familial amyloid polyneuropathy,
4. improve dizziness, light-headed feelings, dizziness on standing up, lassitude and feeling of weariness occurred in hemodialysis patients who have orthostatic hypotension.

Contraindications and precautions: do not use in pregnant and breastfeeding women. Do not use in patients with glaucoma, ventricular tachycardia, or cocaine addiction. Do not use for dialysis patients who have peripheral vascular lesion such as diabetic gangrene.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of DOPS OD tablets 100 mg from Japan for improving nerve function (droxidopa, Northera)

For the improvement of freezing of gait, and dizziness on standing up caused by Parkinson disease: for adults, start with 1 tablet once a day as an initial dose. Then increase the dose by 1 tablet every other day until the optimum dose. The standard maintenance daily dose is 2 tablets at a time, 3 times a day, but the dose may be adjusted by the consulting doctor according to age and symptoms. The maximum dose of 9 tablets a day should not be exceeded.

For the improvement of orthostatic hypotension, faint, and dizziness on standing up caused by Shy-Drager syndrome or familial amyloid polyneuropathy: for adults, start with 2-3 tablets divided into in 2-3 times a day. Then increase the dose by 1 tablet a day every several to 7 days until the optimum dose. The standard maintenance daily dose is 1-2 tablets at a time, 3 times a day, but the dose may be adjusted by the consulting doctor according to age and symptoms. The maximum dose of 9 tablets a day should not be exceeded.

For the improvement of dizziness, light-headed feelings, dizziness on standing up, lassitude, and feeling of weariness in hemodialysis patient with orthostatic hypotension: for adults, take 2-4 tablets 30 to 60 minutes before receiving hemodialysis, but the dose may be reduced by the consulting doctor according to age and symptoms. The maximum dose of 4 tablets at a time should not be exceeded.

This medicine can be taken with or without water. If you use it without water, moisten the tablet with saliva on the tongue and crush it lightly with the tongue, then swallow it with saliva.

How effective are Japanese DOPS OD tablets 100 mg for improving nerve function (droxidopa, Northera)?

DOPS OD tablets contain droxidopa, a synthetic amino acid precursor which acts as a prodrug to the neurotransmitter norepinephrine. It drastically differs from the norepinephrine itself by the ability to cross the blood-brain barrier. DOPS OD tablets effectively increase the concentrations of neurotransmitters in the body and brain and, by this, improve the nerve function.

Who should take DOPS OD tablets 100 mg from Japan?

DOPS OD tablets help to treat such symptoms of nerve function disorders as freezing of gait, dizziness on standing up and dizziness, orthostatic hypotension, faint, light-headed feelings, lassitude and feeling of weariness. This medicine can be used for patients with Parkinson’s disease, Shy-Drager syndrome, familial amyloid polyneuropathy and hemodialysis patients who have orthostatic hypotension. Multiple studies showed that droxidopa is well-tolerated, has few side effects, most of those adverse effects come in a very mild form (H. Kaufmann, R. Freeman et al. "Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial". Neurology, 2014, July, 83 (4): 328–35).